Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

Description: The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to this new report. The rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and the increasing awareness levels amongst the healthcare professionals and the patients pertaining to these diseases are driving the anti-infective agents market.

Organizations, such as the WHO and CDC are actively involved in spreading awareness amongst people regarding the implications of infectious diseases, which are fatal in nature and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and enhance the treatment rates for communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, the introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP) in the near future, are expected to favor the market growth.

Further key findings from the study suggest:

The antibacterial segment was observed to account for the largest share of over 54.0% in 2015. The large market share is attributed to the fact that antibacterials are preferred as the first line of treatment for a large range of infections, the high prescription rates exhibited by this segment, and the increased accessibility of the antibacterials due to their over-the-counter status.

The development of combination drugs to treat and prevent, serious and life-threatening infections is expected to accentuate the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, which is a comprehensive treatment regimen inclusive of four drugs(cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record.

The anti-viral agents segment is expected to grow at a swift CAGR of over 3.5% owing to the high price associated with the introduction of new potent anti-viral drugs such as Vicriviroc for HIV treatment purpose.

North America dominated the overall anti-infective agents market in terms of revenue of over 25.0 billion in 2015. The rise in prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with the increased accessibility to non-prescription anti-infectives in the market are the factors responsible for its dominance.

Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet market demand for novel drugs, rapid improvements in healthcare infrastructure coupled with the rising awareness amongst healthcare professionals as well as patients.

Some of the major companies operating in this market are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc, Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and Novartis AG.

Effective disease management involves a range of long-term strategies such as new product development, merger and acquisitions, co-development, and expansion. For instance, in 2015, ReViral has received a funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.
6.3.3 Gilead Sciences Inc.
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.3.3.3 Product Benchmarking
6.3.3.4 Strategic Initiatives
6.3.4 Bristol-Myers Squibb & Co
6.3.4.1 Company Overview
6.3.4.2 Financial Performance
6.3.4.3 Product Benchmarking
6.3.4.4 Strategic Initiatives
6.3.5 Bayer Healthcare AG
6.3.5.1 Company Overview
6.3.5.2 Financial Performance
6.3.5.3 Product Benchmarking
6.3.5.4 Strategic Initiatives
6.3.6 AstraZeneca plc
6.3.6.1 Company Overview
6.3.6.2 Financial Performance
6.3.6.3 Product Benchmarking
6.3.6.4 Strategic Initiatives
6.3.7 Boehringer Ingelheim GmbH
6.3.7.1 Company Overview
6.3.7.2 Financial Performance
6.3.7.3 Product Benchmarking
6.3.7.4 Strategic Initiatives
6.3.8 Novartis AG
6.3.8.1 Company Overview
6.3.8.2 Financial Performance
6.3.8.3 Product Benchmarking
6.3.8.4 Strategic Initiatives
6.3.9 Sanofi Aventis S.A.
6.3.9.1 Company Overview
6.3.9.2 Financial Performance
6.3.9.3 Product Benchmarking
6.3.9.4 Strategic Initiatives
6.3.10 Johnson & Johnson Inc.
6.3.10.1 Company Overview
6.3.10.2 Financial Performance
6.3.10.3 Product Benchmarking
6.3.10.4 Strategic Initiatives
6.3.11 GlaxoSmithKline Plc
6.3.11.1 Company Overview
6.3.11.2 Financial Performance
6.3.11.3 Product Benchmarking
6.3.11.4 Strategic Initiatives

List of Tables

Table 1 Anti-infective Agents-Market Driver Analysis
Table 2 North America Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 3 North America Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 4 North America Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 5 U.S. Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 6 U.S. Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 7 U.S. Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 8 Canada Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 9 Canada Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 10 Canada Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 11 Europe Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 12 Europe Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 13 Europe Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 14 Germany Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 15 Germany Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 16 Germany Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 17 UK Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 18 UK Antibacterial market, by drug class, 2013 - 2024 (USD Million)
Table 19 UK Antifungal market, by drug class, 2013 - 2024 (USD Million)
Table 20 France Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 21 France Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 22 France Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 23 Asia Pacific Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 24 Asia Pacific Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 25 Asia Pacific Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 26 Japan Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 27 Japan Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 28 Japan Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 29 India Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 30 India Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 31 India Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 32 China Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 33 China Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 34 China Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 35 Brazil Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 36 Brazil Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 37 Brazil Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 38 Mexico Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 39 Mexico Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 40 Mexico Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 41 MEA Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 42 MEA Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 43 MEA Antifungals market, by drug class, 2013 - 2024 (USD Million)
Table 44 South Africa Anti-infective agents market, by type, 2013 - 2024 (USD Million)
Table 45 South Africa Antibacterials market, by drug class, 2013 - 2024 (USD Million)
Table 46 South Africa Antifungals market, by drug class, 2013 - 2024 (USD Million)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3822900/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024
Web Address: http://www.researchandmarkets.com/reports/3822900/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 4950</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 7950</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 9950</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
</table>
First Name: ___________________________________________ Last Name: _______________________________________
Email Address: * _______________________________________
Job Title: ___________________________________________
Organisation: _________________________________________
Address: ____________________________________________
City: _______________________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________________
Phone Number: _______________________________________
Fax Number: _________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World